Five Prime Therapeutics (FPRX) Shareholder Awm Investment Company Has Increased Position; As Wells Fargo Co New (WFC) Stock Declined, Holder Temasek Holdings Private LTD Has Lowered Its Holding

April 24, 2018 - By Vivian Park

Wells Fargo & Company (NYSE:WFC) Logo

Awm Investment Company Inc increased its stake in Five Prime Therapeutics Inc. (FPRX) by 50% based on its latest 2017Q4 regulatory filing with the SEC. Awm Investment Company Inc bought 50,000 shares as the company’s stock declined 22.41% with the market. The institutional investor held 150,000 shares of the health care company at the end of 2017Q4, valued at $3.29 million, up from 100,000 at the end of the previous reported quarter. Awm Investment Company Inc who had been investing in Five Prime Therapeutics Inc. for a number of months, seems to be bullish on the $599.79M market cap company. The stock increased 3.83% or $0.63 during the last trading session, reaching $17.08. About 484,007 shares traded. Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has declined 52.34% since April 24, 2017 and is downtrending. It has underperformed by 63.89% the S&P500.

Temasek Holdings Private Ltd decreased its stake in Wells Fargo Co New (WFC) by 33.33% based on its latest 2017Q4 regulatory filing with the SEC. Temasek Holdings Private Ltd sold 86,788 shares as the company’s stock declined 16.98% with the market. The institutional investor held 173,576 shares of the major banks company at the end of 2017Q4, valued at $10.53M, down from 260,364 at the end of the previous reported quarter. Temasek Holdings Private Ltd who had been investing in Wells Fargo Co New for a number of months, seems to be less bullish one the $255.10B market cap company. The stock decreased 0.51% or $0.27 during the last trading session, reaching $52.34. About 17.37M shares traded. Wells Fargo & Company (NYSE:WFC) has declined 7.75% since April 24, 2017 and is downtrending. It has underperformed by 19.30% the S&P500.

Temasek Holdings Private Ltd, which manages about $16.27 billion US Long portfolio, upped its stake in Visa Inc (NYSE:V) by 367,700 shares to 3.66M shares, valued at $417.37 million in 2017Q4, according to the filing. It also increased its holding in Emerson Elec Co (NYSE:EMR) by 95,908 shares in the quarter, for a total of 123,908 shares, and has risen its stake in China Biologic Prods Hldgs I.

Investors sentiment increased to 0.75 in Q4 2017. Its up 0.02, from 0.73 in 2017Q3. It increased, as 63 investors sold WFC shares while 746 reduced holdings. 138 funds opened positions while 466 raised stakes. 3.64 billion shares or 0.11% less from 3.65 billion shares in 2017Q3 were reported. Klingenstein Fields & Lc accumulated 58,514 shares. Hwg Hldgs Ltd Partnership invested in 11,551 shares or 0.59% of the stock. The South Dakota-based South Dakota Investment Council has invested 1.92% in Wells Fargo & Company (NYSE:WFC). Utah Retirement System has 823,963 shares for 1.05% of their portfolio. New York-based Ibm Retirement Fund has invested 1.3% in Wells Fargo & Company (NYSE:WFC). Agf Inc holds 455,233 shares. Glynn Management Llc reported 0.25% in Wells Fargo & Company (NYSE:WFC). Cognios Capital Ltd Liability Corp holds 32,601 shares. Payden Rygel holds 1.7% or 322,100 shares. Institute For Wealth Mngmt Lc accumulated 11,195 shares or 0.16% of the stock. Natixis has 613,421 shares for 0.29% of their portfolio. Bradley Foster Sargent Inc Ct accumulated 0.99% or 448,990 shares. Palisades Hudson Asset Mgmt Limited Partnership has invested 0.26% in Wells Fargo & Company (NYSE:WFC). 338,106 were accumulated by Washington Com. Canal Insurance owns 0.83% invested in Wells Fargo & Company (NYSE:WFC) for 38,500 shares.

Since November 17, 2017, it had 0 insider buys, and 1 sale for $292,234 activity.

Among 39 analysts covering Wells Fargo & Company (NYSE:WFC), 15 have Buy rating, 9 Sell and 15 Hold. Therefore 38% are positive. Wells Fargo & Company had 145 analyst reports since July 29, 2015 according to SRatingsIntel. BMO Capital Markets maintained the shares of WFC in report on Wednesday, May 31 with “Sell” rating. Nomura maintained Wells Fargo & Company (NYSE:WFC) on Monday, February 5 with “Buy” rating. The stock of Wells Fargo & Company (NYSE:WFC) has “Neutral” rating given on Friday, October 6 by UBS. The company was upgraded on Wednesday, January 20 by Susquehanna. The firm earned “Buy” rating on Wednesday, August 30 by RBC Capital Markets. The firm has “Hold” rating given on Friday, July 28 by Piper Jaffray. The firm earned “Sell” rating on Friday, July 14 by BMO Capital Markets. The rating was maintained by Nomura on Monday, April 25 with “Buy”. The stock of Wells Fargo & Company (NYSE:WFC) has “Sell” rating given on Wednesday, April 12 by Rafferty. The stock of Wells Fargo & Company (NYSE:WFC) has “Hold” rating given on Friday, October 13 by BMO Capital Markets.

Analysts await Wells Fargo & Company (NYSE:WFC) to report earnings on July, 13. They expect $1.17 EPS, up 9.35% or $0.10 from last year’s $1.07 per share. WFC’s profit will be $5.70 billion for 11.18 P/E if the $1.17 EPS becomes a reality. After $1.12 actual EPS reported by Wells Fargo & Company for the previous quarter, Wall Street now forecasts 4.46% EPS growth.

Awm Investment Company Inc, which manages about $1.06B and $515.30 million US Long portfolio, decreased its stake in Reata Pharmaceuticals Inc. by 111,736 shares to 47,929 shares, valued at $1.36M in 2017Q4, according to the filing. It also reduced its holding in Syros Pharmaceuticals Inc. by 60,000 shares in the quarter, leaving it with 65,000 shares, and cut its stake in Lemaitre Vascular Inc. (NASDAQ:LMAT).

Among 11 analysts covering Five Prime Therapeutics (NASDAQ:FPRX), 11 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Five Prime Therapeutics had 25 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has “Outperform” rating given on Monday, October 16 by BMO Capital Markets. The rating was initiated by Citigroup on Tuesday, October 25 with “Buy”. The rating was maintained by RBC Capital Markets on Monday, November 6 with “Buy”. The stock of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) earned “Outperform” rating by Credit Suisse on Thursday, January 21. The stock of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has “Outperform” rating given on Monday, October 19 by Oppenheimer. The firm has “Buy” rating given on Thursday, February 15 by Guggenheim. Citigroup initiated the stock with “Buy” rating in Friday, July 31 report. The stock of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has “Outperform” rating given on Friday, March 11 by Credit Suisse. The stock has “Hold” rating by BMO Capital Markets on Wednesday, September 20. Jefferies maintained the shares of FPRX in report on Wednesday, June 7 with “Buy” rating.

Investors sentiment increased to 1.34 in Q4 2017. Its up 0.30, from 1.04 in 2017Q3. It improved, as 21 investors sold FPRX shares while 29 reduced holdings. 24 funds opened positions while 43 raised stakes. 25.47 million shares or 6.30% more from 23.96 million shares in 2017Q3 were reported. Fred Alger Mgmt has invested 0% of its portfolio in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Bain Cap Public Equity Mngmt Limited Liability Com holds 38,272 shares or 0.06% of its portfolio. Metropolitan Life Insurance Ny has invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Healthcor Mgmt Lp holds 101,000 shares or 0.07% of its portfolio. Alliancebernstein Ltd Partnership accumulated 46,200 shares or 0% of the stock. Moreover, Ubs Asset Management Americas Incorporated has 0% invested in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) for 96,858 shares. Franklin Street Advisors Nc stated it has 25,000 shares or 0.08% of all its holdings. State Of Wisconsin Investment Board invested in 0% or 20,000 shares. Tudor Investment Et Al stated it has 16,496 shares or 0.01% of all its holdings. Envestnet Asset Mngmt Inc reported 52 shares. California Employees Retirement Systems holds 0% of its portfolio in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) for 22,000 shares. Invesco Ltd has invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Pictet Asset Management Ltd holds 0.02% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) or 427,052 shares. Rhumbline Advisers invested in 0% or 29,492 shares. Meeder Asset Mgmt has invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX).

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts